Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance)
Júlia C.F. Quintanilha, Yingmiao Liu, Amy S. Etheridge, Akram Yazdani, Hedy L. Kindler, William Kevin Kelly, Andrew B. Nixon, Federico Innocenti
Topics & Concepts
BevacizumabMedicineInternal medicineOdds ratioGastroenterologyLogistic regressionConfidence intervalClinical endpointClinical trialOncologyChemotherapyAngiogenesis and VEGF in CancerCancer Treatment and PharmacologyAntiplatelet Therapy and Cardiovascular Diseases